The glutamate/IL-6 ratio showed a remarkable specificity and sensitivity, higher than 95%, with the capacity to identify patients with a latency time of 0–2 h, which could prove a useful tool for developing a marker to identify patients within the time frame for reperfusion treatments, including patients with a wake-up stroke. The gene discussed is IL6; the disease is Stroke.